EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 15-Oct-2025 08:11 ET (15-Oct-2025 12:11 GMT/UTC)

Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer

Ben-Gurion University of the Negev
Peer-Reviewed Publication

Prof. Schvartzman and Prof. Porgador have designed artificial nanostructured surfaces specifically optimized for generating potent CAR T cells with long-lasting immunotherapeutic activity.

Journal: Advanced Materials

Beyond the pandemic: Nurses on a mission to defeat the world’s deadliest disease

European Society of Cardiology
Meeting Announcement

Cardiovascular disease (CVD) is the leading cause of death worldwide.

In France as many women die from cardiovascular disease as cancer.

ACNAP 2025 aims to bring together professionals who provide daily care and support to patients and their support networks.

HKU biologists uncover how a genetic player fuels liver cancer by disrupting fat metabolism

The University of Hong Kong
Peer-Reviewed Publication

Liver cancer is a lethal disease with limited treatment options for advanced stages. While risk factors such as viral hepatitis, alcohol use, and obesity increase the likelihood of hepatocellular carcinoma (HCC, the progression of liver cancer), scientists are racing to uncover the hidden biological mechanisms that fuel tumour growth. Recent research led by Professor Jiangwen ZHANG of the School of Biological Sciences at The University of Hong Kong (HKU) has uncovered how a key genetic culprit, VPS72, drives the development of liver cancer by disrupting fat metabolism and manipulating gene activity. The team’s findings have been published in Advanced Science.

Journal: Advanced Science

Innovative HKUMed treatment results in complete long-term remission of advanced liver cancer without surgery in 46% of patients in study

The University of Hong Kong
Peer-Reviewed Publication

An interdisciplinary research team from the Department of Surgery and Department of Clinical Oncology, School of Clinical Medicine at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has demonstrated a durable and lasting response to a novel treatment – combined locoregional therapy and immunotherapy (LRT-IO) – for advanced liver cancer patients. The study marks the first investigation into the long-term outcomes for patients with locally advanced liver cancer receiving this treatment. The researchers identified key factors associated with a complete response, and found that this pioneering approach is safe, effective and sustainable. The findings were recently published in the journal JAMA Oncology.

Journal: JAMA Oncology

‘AI scientist’ suggests combinations of widely available non-cancer drugs can kill cancer cells

University of Cambridge
Peer-Reviewed Publication

An ‘AI scientist’, working in collaboration with human scientists, has found that combinations of cheap and safe drugs – used to treat conditions such as high cholesterol and alcohol dependence – could also be effective at treating cancer, a promising new approach to drug discovery.

Journal: Journal of The Royal Society Interface

Dr. Nikolaos Koundouros wins 2025 Tri-Institutional Breakout Award

Weill Cornell Medicine
Grant and Award Announcement

Dr. Nikolaos Koundouros, a postdoctoral associate in the Department of Pharmacology at Weill Cornell Medicine, has been awarded a 2025 Tri-Institutional Breakout Award for Junior Investigators.

Study identifies proteins involved in the effectiveness of immunotherapy against blood cancer

Fundação de Amparo à Pesquisa do Estado de São Paulo
Peer-Reviewed Publication

Researchers at a FAPESP-supported research center have discovered 14 proteins that could be targets for improving CAR-T cell-based therapies.

Journal: Journal of Proteome Research
Funder: Fundação de Amparo à Pesquisa do Estado de São Paulo

Pancreatic cancer spreads to liver or lung thanks to this protein

University of California - San Francisco
Peer-Reviewed Publication

Scientists at UC San Francisco have discovered how pancreatic cancer cells thrive in the lungs or liver, environments that are as distinct to cells as the ocean and desert are to animals. The spread of cancer cells to organs like these often produces the very first symptoms of pancreatic cancer. But by that time, the pancreatic cancer has spread out of control.

Journal: Nature
Funder: U.S. National Science Foundation, NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, Belgian American Educational Foundation, Fonds Léon Fredericq, Rotary and Wallonie Bruxelles International, Ed Marra Passion to Win Fund, Weston Havens Foundation, AACR-MPM Transformative Cancer Research Award

New tool to generate aneuploidies and analyze their impact on development

Institute for Research in Biomedicine (IRB Barcelona)
Peer-Reviewed Publication

Aneuploidy—the presence of an incorrect number of chromosomes—is common during the normal development of human embryos and is the main cause of spontaneous miscarriage.

A team of researchers at IRB Barcelona has developed a genetic tool to create customized aneuploidies and analyse their impact during development.

Published in Cell Genomics, the study demonstrates that aneuploid cells are actively eliminated by neighbouring cells through cell competition.

These mechanisms may be involved in the removal of aneuploid cells during early human development.

Journal: Cell Genomics

Five-year analysis shows immunotherapy plus chemotherapy before lung cancer surgery significantly improves long-term survival

Johns Hopkins Medicine
Peer-Reviewed Publication

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — improved long-term survival overall compared with chemotherapy alone, according to a landmark study published June 2 in the New England Journal of Medicine.

Journal: New England Journal of Medicine
Funder: Bristol-Myers Squibb, Ono Pharmaceutical Company Ltd.